至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Belinostat resolves skin barrier defects in atopic dermatitis by targeting the dysregulated miR-335:SOX6 axis

J Allergy Clin Immunol. 2020-02-01; 
Wen Chiy Liew, Gopinath M Sundaram, Shan Quah, Guo Guang Lum, Jonathan S L Tan, Rajkumar Ramalingam, John E A Common, Mark B Y Tang, E Birgitte Lane, Steven Tien Guan Thng, Prabha Sampath
Products/Services Used Details Operation
Mutant Libraries … Details of the antibodies used in the study are provided in Table E3. Dual luciferase reporter assay. Luciferase reporter constructs containing the wild-type and mutant 3'-untranslated regions (3'-UTRs) of SOX6 were purchased from GenScript Get A Quote

摘要

background: Atopic dermatitis (AD) is a common chronic inflammatory skin disease. Skin barrier defects contribute to disease initiation and development; however, underlying mechanisms remain elusive. objective: To understand the underlying cause of barrier defect, we investigated aberrant expression of specific microRNAs (miRNAs) in AD. Delineating the molecular mechanism of dysregulated miRNA network, we focused on identification of specific drugs that can modulate miRNA expression and repair the defective barrier in AD. methods: A screen for differentially expressed miRNAs between healthy skin and AD lesional skin resulted in the identification of miR-335 as the most consistently downregulated miRNA in AD. Us... More

关键词

MicroRNA, atopic dermatitis, barrier defect, chronic inflammation